Published in J Immunol on May 12, 2017
Universal sample preparation method for proteome analysis. Nat Methods (2009) 16.88
T cell tolerance by clonal elimination in the thymus. Cell (1987) 13.83
Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc (2007) 10.71
The nonsense-mediated decay RNA surveillance pathway. Annu Rev Biochem (2007) 8.94
T cell anergy. Annu Rev Immunol (2001) 7.15
Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med (2010) 4.28
Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nat Immunol (2006) 3.85
Upf1 phosphorylation triggers translational repression during nonsense-mediated mRNA decay. Cell (2008) 3.26
Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol (1996) 2.88
Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther (2011) 2.75
Blocked Ras activation in anergic CD4+ T cells. Science (1996) 2.64
Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther (2010) 2.51
Leucine-tRNA initiates at CUG start codons for protein synthesis and presentation by MHC class I. Science (2012) 2.30
Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol (1996) 2.12
Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther (2002) 1.98
Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther (2001) 1.93
Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum Mutat (2006) 1.61
Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes. Nat Rev Mol Cell Biol (2015) 1.61
Plasmacytoid dendritic cells transport peripheral antigens to the thymus to promote central tolerance. Immunity (2012) 1.57
Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest (2007) 1.57
Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther (2001) 1.54
Alternative translation start sites and hidden coding potential of eukaryotic mRNAs. Bioessays (2008) 1.53
Scanning detection of mutations in human ornithine transcarbamoylase by chemical mismatch cleavage. Proc Natl Acad Sci U S A (1989) 1.50
Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther (2009) 1.49
Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc Natl Acad Sci U S A (2006) 1.48
Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation. Proc Natl Acad Sci U S A (2011) 1.40
Clonal deletion and the fate of autoreactive thymocytes that survive negative selection. Nat Immunol (2012) 1.28
Kinetics of antigen expression and epitope presentation during virus infection. PLoS Pathog (2013) 1.21
Alternative translation start sites are conserved in eukaryotic genomes. Nucleic Acids Res (2010) 1.15
Identification of RNA splicing errors resulting in human ornithine transcarbamylase deficiency. Am J Hum Genet (1991) 1.13
Distinct pathways generate peptides from defective ribosomal products for CD8+ T cell immunosurveillance. J Immunol (2011) 1.09
Liver gene therapy: advances and hurdles. Gene Ther (2004) 1.06
Non-conventional sources of peptides presented by MHC class I. Cell Mol Life Sci (2011) 1.03
Defective ribosomal products are the major source of antigenic peptides endogenously generated from influenza A virus neuraminidase. J Immunol (2009) 1.02
Origin and plasticity of MHC I-associated self peptides. Autoimmun Rev (2011) 0.99
Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome. Mol Genet Metab (2011) 0.96
Differentiation of transient hyperammonemia of the newborn and urea cycle enzyme defects by clinical presentation. J Pediatr (1985) 0.92
Activation of CFTR-specific T Cells in cystic fibrosis mice following gene transfer. Mol Ther (2007) 0.91
Ornithine transcarbamylase deficiency: characterization of gene mutations and polymorphisms. Hum Mutat (1996) 0.90
Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J Transl Med (2014) 0.89
Induction of immune tolerance by dendritic cells: implications for preventative and therapeutic immunotherapy of autoimmune disease. Immunol Cell Biol (2002) 0.88
Substrate-induced protein stabilization reveals a predominant contribution from mature proteins to peptides presented on MHC class I. J Immunol (2013) 0.85
Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. PLoS One (2014) 0.85
Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases. Front Immunol (2015) 0.83
Readthrough transcription: How are DoGs made and what do they do? RNA Biol (2016) 0.81
Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3' UTR. Proc Natl Acad Sci U S A (2014) 0.80
The ornithine transcarbamylase (OTC) gene: mutations in 50 Japanese families with OTC deficiency. Am J Med Genet (1997) 0.80
Nowhere to hide: unconventional translation yields cryptic peptides for immune surveillance. Immunol Rev (2016) 0.78
Identification of four novel splice site mutations in the ornithine transcarbamylase gene. Hum Genet (1996) 0.77
Novel intragenic deletions and point mutations of the ornithine transcarbamylase gene in congenital hyperammonemia. Hum Mutat (1998) 0.76